Combinatorial Assembly of Small Molecules into Bivalent Antagonists of TrkC or TrkA Receptors

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Mar 8

PMID 24603864

Citations 8

Authors

Fouad Brahimi

Eunhwa Ko

Andrey Malakhov

Kevin Burgess

H Uri Saragovi

Affiliations

Soon will be listed here.

Abstract

A library of peptidomimetics was assembled combinatorially into dimers on a triazine-based core. The pharmacophore corresponds to β-turns of the neurotrophin polypeptides neurotrophin-3 (NT-3), nerve growth factor (NGF), or brain-derived neurotrophic factor (BDNF). These are the natural ligands for TrkC, TrkA, and TrkB receptors, respectively. The linker length and the side-chain orientation of each monomer within the bivalent mimics were systematically altered, and the impact of these changes on the function of each ligand was evaluated. While the monovalent peptidomimetics had no detectable binding or bioactivity, four bivalent peptidomimetics (2c, 2d, 2e, 3f) are selective TrkC ligands with antagonistic activity, and two bivalent peptidomimetics (1a, 1b) are TrkC and TrkA ligands with antagonistic activity. All these bivalent compounds block ligand-dependent receptor activation and cell survival, without affecting neuritogenic differentiation. This work adds to our understanding of how the neurotrophins function through Trk receptors, and demonstrates that peptidomimetics can be designed to selectively disturb specific biological signals, and may be used as pharmacological probes or as therapeutic leads. The concept of altering side-chain, linker length, and sequence orientation of a subunit within a pharmacophore provides an easy modular approach to generate larger libraries with diversified bioactivity.

Citing Articles

Selective inhibitors of the TrkC.T1 receptor reduce retinal inflammation and delay neuronal death in a model of retinitis pigmentosa.

Brahimi F, Nassour H, Galan A, Guruswamy R, Ortiz C, Nejatie A PNAS Nexus. 2025; 4(2):pgaf020.

PMID: 39911316 PMC: 11795507. DOI: 10.1093/pnasnexus/pgaf020.

Selective, Intrinsically Fluorescent Trk Modulating Probes.

Pewklang T, Thompson T, Sefiani A, Geoffroy C, Kamkaew A, Burgess K ACS Chem Neurosci. 2024; .

PMID: 39356215 PMC: 11487604. DOI: 10.1021/acschemneuro.4c00290.

Unveiling functional motions based on point mutations in biased signaling systems: A normal mode study on nerve growth factor bound to TrkA.

Resende-Lara P, Perahia D, Scott A, Braz A PLoS One. 2020; 15(6):e0231542.

PMID: 32497034 PMC: 7272051. DOI: 10.1371/journal.pone.0231542.

Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration.

Saragovi H, Galan A, Levin L Front Cell Neurosci. 2019; 13:231.

PMID: 31244606 PMC: 6563757. DOI: 10.3389/fncel.2019.00231.

A C-terminal cysteine residue is required for peptide-based inhibition of the NGF/TrkA interaction at nM concentrations: implications for peptide-based analgesics.

Poole A, Frigotto L, Smith M, Baar C, Ivanova-Berndt G, Jaulent A Sci Rep. 2019; 9(1):930.

PMID: 30700786 PMC: 6353895. DOI: 10.1038/s41598-018-37585-5.

References

Pattarawarapan M, Zaccaro M, Saragovi U, Burgess K . New templates for syntheses of ring-fused, C(10) beta-turn peptidomimetics leading to the first reported small-molecule mimic of neurotrophin-3. J Med Chem. 2002; 45(20):4387-90. DOI: 10.1021/jm0255421. View

Lee H, Zaccaro M, Pattarawarapan M, Roy S, Saragovi H, Burgess K . Syntheses and activities of new C10 beta-turn peptidomimetics. J Org Chem. 2004; 69(3):701-13. DOI: 10.1021/jo034167x. View

Saragovi H, Zheng W, Maliartchouk S, DiGugliemo G, Mawal Y, Kamen A . A TrkA-selective, fast internalizing nerve growth factor-antibody complex induces trophic but not neuritogenic signals. J Biol Chem. 1998; 273(52):34933-40. DOI: 10.1074/jbc.273.52.34933. View

Kaplan D, Miller F . Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000; 10(3):381-91. DOI: 10.1016/s0959-4388(00)00092-1. View

Chen D, Brahimi F, Angell Y, Li Y, Moscowicz J, Saragovi H . Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals. ACS Chem Biol. 2009; 4(9):769-81. PMC: 2756187. DOI: 10.1021/cb9001415. View

Ko E, Liu J, Burgess K . Minimalist and universal peptidomimetics. Chem Soc Rev. 2011; 40(8):4411-21. DOI: 10.1039/c0cs00218f. View

Marshall C . Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995; 80(2):179-85. DOI: 10.1016/0092-8674(95)90401-8. View

Chao M, Bothwell M . Neurotrophins: to cleave or not to cleave. Neuron. 2002; 33(1):9-12. DOI: 10.1016/s0896-6273(01)00573-6. View

Hempstead B . The many faces of p75NTR. Curr Opin Neurobiol. 2002; 12(3):260-7. DOI: 10.1016/s0959-4388(02)00321-5. View

10.

LeSauteur L, Cheung N, Lisbona R, Saragovi H . Small molecule nerve growth factor analogs image receptors in vivo. Nat Biotechnol. 1996; 14(9):1120-2. DOI: 10.1038/nbt0996-1120. View

11.

Maliartchouk S, Debeir T, Beglova N, Cuello A, Gehring K, Saragovi H . Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action. J Biol Chem. 2000; 275(14):9946-56. DOI: 10.1074/jbc.275.14.9946. View

12.

Ivanisevic L, Zheng W, Woo S, Neet K, Saragovi H . TrkA receptor "hot spots" for binding of NT-3 as a heterologous ligand. J Biol Chem. 2007; 282(23):16754-63. DOI: 10.1074/jbc.M701996200. View

13.

Brahimi F, Malakhov A, Lee H, Pattarawarapan M, Ivanisevic L, Burgess K . A peptidomimetic of NT-3 acts as a TrkC antagonist. Peptides. 2009; 30(10):1833-9. PMC: 2755609. DOI: 10.1016/j.peptides.2009.07.015. View

14.

Brahimi F, Liu J, Malakhov A, Chowdhury S, Purisima E, Ivanisevic L . A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist. Biochim Biophys Acta. 2010; 1800(9):1018-26. PMC: 2943489. DOI: 10.1016/j.bbagen.2010.06.007. View

15.

Mahadeo D, Kaplan L, Chao M, Hempstead B . High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors. J Biol Chem. 1994; 269(9):6884-91. View

16.

Ivanisevic L, Banerjee K, Saragovi H . Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75. Oncogene. 2003; 22(36):5677-85. DOI: 10.1038/sj.onc.1206864. View

17.

Beglova N, Maliartchouk S, Ekiel I, Zaccaro M, Saragovi H, Gehring K . Design and solution structure of functional peptide mimetics of nerve growth factor. J Med Chem. 2000; 43(19):3530-40. DOI: 10.1021/jm990441x. View

18.

Angell Y, Chen D, Brahimi F, Saragovi H, Burgess K . A combinatorial method for solution-phase synthesis of labeled bivalent beta-turn mimics. J Am Chem Soc. 2007; 130(2):556-65. DOI: 10.1021/ja074717z. View

19.

Zaccaro M, Lee H, Pattarawarapan M, Xia Z, Caron A, LHeureux P . Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chem Biol. 2005; 12(9):1015-28. DOI: 10.1016/j.chembiol.2005.06.015. View

20.

Maliartchouk S, Saragovi H . Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands. J Neurosci. 1997; 17(16):6031-7. PMC: 6568372. View